Table 1 Criteria for inclusion and exclusion of patients

Full-size liver transplantation

Split liver transplantation or living donor related liver transplantation

Informed consent of the patient or legal representative

Participation on other clinical trials 30 days prior to randomization

Age ≥ 18 years

Retransplantation or multivisceral transplantation

Respiratory and/or circulatory instability (noradrenaline > 1μg/kgBW/min and FiO₂ > 0,6)

Conditions in which bleeding complications may be expected from the effect of Iloprost on platelets

Known allergy or intolerance against trial medication, tacrolimus, mycophenolat mofetil, basiliximab or corticosteroids

Severe coronary artery disease or unstable angina pectoris

Myocardial infarction within the past 6 months prior to randomization

Acute or chronic heart failure (NYHA II-IV)

Cardiac arrhythmias relevant for the prognosis

Suspected pulmonary artery congestion

Women of child-bearing potential except women with the following criteria:

 ○ post menopausal

 ○ sterilization 86 weeks after bilateral ovarectomy

 ○ using an effective method of contraception during the trial

 ○ sexual abstinence or vasectomised partner

Pregnancy/lactation